When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful development and approval.
In this case study, Phastar helped investigate a failed European bioequivalence study, identify the statistical factors behind the outcome, and support a successful regulatory strategy.
Download the full case study to discover how Phastar helps sponsors address regulatory challenges through expert statistical consultancy and evidence-based decision-making.